OR WAIT 15 SECS
Throughout this trial, YPrime will be supporting world class selected sites to conduct the study with data driven metrics pulled from these tools. YPrime is dedicated to applying its leading edge eClinical technology to help forward unmet medical needs in the Biotech and Pharmaceutical industry.
Y-Prime, Inc., announced it has been awarded an international Phase II clinical trial from a virtual biopharma company to assess a new treatment for patients with Non-Small Cell Lung Carcinoma (NSCLC). This study will be conducted utilizing the company's proprietary eClinical Supply Forecasting tool (eCSF) and Interactive Response Technology (IRT) solution. ClinicalTrials.gov lists the Phase II trials for NSCLC here.